{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:47:28Z","timestamp":1765961248681,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s13760-020-01370-x","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T12:02:36Z","timestamp":1590148956000},"page":"1351-1356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Aripiprazole-induced Parkinsonism with pregabalin as a confounder"],"prefix":"10.1007","volume":"121","author":[{"given":"Upinder","family":"Kaur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bisweswar","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhairav Kumar","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indrajeet Singh","family":"Gambhir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7737-0016","authenticated-orcid":false,"given":"Sankha Shubhra","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"1370_CR1","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40263-015-0278-3","volume":"29","author":"A de Bartolomeis","year":"2015","unstructured":"de Bartolomeis A, Tomasetti C, Iasevoli F (2015) Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs 29:773\u2013799","journal-title":"CNS Drugs"},{"key":"1370_CR2","volume-title":"Goodman and Gilman\u2019s the pharmacological basis of therapeutics","author":"LL Brunton","year":"2018","unstructured":"Brunton LL, Hilal-Dandan R, Knollmann BC (2018) Goodman and Gilman\u2019s the pharmacological basis of therapeutics. McGraw Hill Education, New York"},{"key":"1370_CR3","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.3109\/00207450903225553","volume":"119","author":"DA Hall","year":"2009","unstructured":"Hall DA, Agarwal P, Griffith A et al (2009) Movement disorders associated with aripiprazole use: a case series. Int J Neurosci 119:2274\u20132279","journal-title":"Int J Neurosci"},{"key":"1370_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/JCP.0b013e3182856826","volume":"33","author":"MH Chen","year":"2013","unstructured":"Chen MH, Liou YJ (2013) Aripiprazole-associated acute dystonia, akathisia, and parkinsonism in a patient with bipolar I disorder. J Clin Psychopharmacol 33:269\u2013270","journal-title":"J Clin Psychopharmacol"},{"key":"1370_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/NRL.0000000000000096","volume":"22","author":"K Selfani","year":"2017","unstructured":"Selfani K, Soland VL, Chouinard S et al (2017) Movement disorders induced by the \u201cAtypical\u201d antipsychotic aripiprazole. Neurologist 22:24\u201328","journal-title":"Neurologist"},{"key":"1370_CR6","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/JCP.0000000000000750","volume":"37","author":"A J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen A, Thorleifsson A, Jimenez-Solem E et al (2017) Severe Parkinsonism and creatine kinase increase after low-dose aripiprazole treatment in a patient of African descent. J Clin Psychopharmacol 37:630\u2013631","journal-title":"J Clin Psychopharmacol"},{"key":"1370_CR7","first-page":"PCC.10l01081","volume":"13","author":"H Patel","year":"2011","unstructured":"Patel H, Patel A, Mushtaq S et al (2011) Aripiprazole-induced Parkinsonism in a child: a case report. Prim Care Companion CNS Disord 13:PCC.10l01081","journal-title":"Prim Care Companion CNS Disord"},{"key":"1370_CR8","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1186\/1752-1947-3-6448","volume":"3","author":"LL Lua","year":"2009","unstructured":"Lua LL, Zhang L (2009) Development of Parkinsonism following exposure to aripiprazole: two case reports. J Med Case Rep 3:6448","journal-title":"J Med Case Rep"},{"key":"1370_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1177\/0269881108098145","volume":"24","author":"A Caykoylu","year":"2010","unstructured":"Caykoylu A, Ekinci O, Kuloglu M et al (2010) Aripiprazole-induced rabbit syndrome: a case report. J Psychopharmacol (Oxford) 24:429\u2013431","journal-title":"J Psychopharmacol (Oxford)"},{"key":"1370_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/WNF.0b013e3181a9eb1b","volume":"32","author":"LS Perez","year":"2009","unstructured":"Perez LS, Amaya M, Merello M (2009) Pregabalin-induced parkinsonism: a case report. Clin Neuropharmacol 32:353\u2013354","journal-title":"Clin Neuropharmacol"},{"key":"1370_CR11","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/jppr.1363","volume":"48","author":"E Prado-Mel","year":"2018","unstructured":"Prado-Mel E, Gil-L\u00f3pez M, Navarro-Corrales MD (2018) Pregabalin-induced parkinsonism 72 hours after iodinated contrast administration. J Pharm Pract Res 48:368\u2013371","journal-title":"J Pharm Pract Res"},{"key":"1370_CR12","first-page":"046","volume":"18","author":"GF Ma","year":"2014","unstructured":"Ma GF, Raivio N, Sabri\u00e0 J, Ortiz J (2014) Agonist and antagonist effects of aripiprazole on D2-like receptors controlling rat brain dopamine synthesis depend on the dopaminergic tone. Int J Neuropsychopharmacol 18:046","journal-title":"Int J Neuropsychopharmacol"},{"key":"1370_CR13","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s10072-018-3662-1","volume":"40","author":"U Kaur","year":"2019","unstructured":"Kaur U, Das P, Gambhir IS et al (2019) L-type calcium channel blockers and a symptom complex mimicking de Melo-Souza\u2019s syndrome. Neurol Sci 40:1077\u20131080","journal-title":"Neurol Sci"},{"key":"1370_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jns.2009.05.006","volume":"284","author":"HI Ma","year":"2009","unstructured":"Ma HI, Kim JH, Chu MK et al (2009) Diabetes mellitus and drug-induced parkinsonism: a case\u2013control study. J Neurol Sci 284:140\u2013143","journal-title":"J Neurol Sci"},{"key":"1370_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.parkreldis.2019.12.011","volume":"70","author":"S de Germay","year":"2020","unstructured":"de Germay S, Montastruc F, Carvajal A et al (2020) Drug-induced parkinsonism: revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism Relat Disord 70:55\u201359","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-020-01370-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-020-01370-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-020-01370-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T12:41:23Z","timestamp":1631709683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-020-01370-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1370"],"URL":"https:\/\/doi.org\/10.1007\/s13760-020-01370-x","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"type":"print","value":"0300-9009"},{"type":"electronic","value":"2240-2993"}],"subject":[],"published":{"date-parts":[[2020,5,22]]},"assertion":[{"value":"15 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards:"}},{"value":"Dr Chakrabarti received lecture honorarium from Novartis and Consultancy honorarium from Intas Pharmaceuticals, Lupin and Alkem. None of the other authors report any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animals rights"}},{"value":"Written informed consent taken from patient and his legal guardian (son) for publication of case details and video images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}